Partnership with Providence “immediately establishes Everest as a major mRNA player in ...
Elise Mak · 09/16/2021
Everest Medicines is the latest to join the course by tapping the mRNA technology, an area that Chinese players are flocking to.
READ MORE
South Australia an ideal start for biotech R&D
Elise Mak · 09/15/2021
Representatives of these players offered their insights to Chinese biotech companies at the South Australia ∙ Clinical Trials Ecosystem – China Event Series zoom webinar on Sep. 13.
READ MORE
A Look at the Key Players in China's ADC Market
· 08/29/2021
ADCs in China tracked by company,licensing,and fundraising.
READ MORE
China Biopharma IPOs: A Summary of H1 2021
Minhua Chu · 08/23/2021
In the first half of 2021, nine Chinese drug developers completed initial public offerings (IPOs), raising an average of $243.4 million.
READ MORE
ADCs are on the Rise in China
· 08/06/2021
Three ADCs have been approved by NMPA.
READ MORE
Antibody Licensing Deals in China: H1 2021 Summary
Minhua Chu · 07/29/2021
Nineteen antibody deals were closed in H1 2021.
READ MORE
Do NMPA Approvals Cause Share Prices to Rise?
Shi Yingzi · 07/29/2021
three fourths of stocks to rise on the day of approval.
READ MORE
The Chinese Government is Taking Initiatives to Enha...
editor · 07/19/2021
Improve the system of laws and regulations. Speed up their formulation and revision and advance technical guidelines in an orderly manner.
READ MORE
The Advantages of Getting Breakthrough Therapy Desig...
editor · 07/19/2021
On July 1, 2020, the latest Drug Registration Regulations were enacted. This new set of regulations introduced four accelerated procedures for BTDs therapy, conditional approval, priority review and approval, and special approval.
READ MORE
READ MORE
Copyright © 2016-2021 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement